John Oluwafemi Teibo is a Postdoctoral Fellow in the Laboratory of Translational Oncology at the Ribeirão Preto Medical School, University of São Paulo, Brazil. He holds a PhD in Biochemistry from the University of São Paulo and was a visiting PhD researcher at the MRC Protein Phosphorylation and Ubiquitylation Unit (MRC PPU), University of Dundee, UK. His doctoral research applied advanced proteomics and phosphoproteomics to elucidate the molecular mechanisms of anti-CD19 CAR-T cell therapy. His current postdoctoral research integrates plasma proteomics and polygenic risk scores to identify biomarkers for precision risk stratification and early detection of breast and prostate cancer. His research interests include cancer proteomics, phosphoproteomics, proteogenomics, cancer immunotherapy, and precision oncology. Teibo serves as an Editorial Board Member of Essays in Biochemistry and is a member of the American Society for Pharmacology and Experimental Therapeutics (ASPET), the European Association for Cancer Research (EACR), and the Biochemical Society. His research has been recognized with several competitive awards, including the ASPET Best Poster Award (Postdoctoral Category), the Royal Society of Chemistry Researchers Collaboration Grant, the Biochemical Society Lab Visit Grant, the EACR Travel Fellowship, and the IUBMB Wood-Whelan Research Fellowship.